{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(1)"],"submitter":["Abdul-Rahman U"],"pubmed_abstract":["LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival (OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer (TNBC) as compared with Luminal-A, Luminal-B, and HER2 breast cancer subtypes. ERRLR01 levels were also inversely correlated with breast cancer survival across all breast cancer patients. Upon stratification, OS in ERα<sup>-</sup> tumors correlated with negative overall survival, while in ERα<sup>+</sup> tumors, ERRLR01 correlated with positive outcomes. This suggests ERRLR01 is modulated by hormone signaling in breast cancer. Gene-network analysis revealed ERRLR01 correlated with distinct pathways including \"epithelial development\" and \"cellular differentiation.\" These data suggest ERRLR01 operates as an oncogene in TNBC, as well as a biomarker in breast cancer patients."],"journal":["Transcription"],"pagination":["17-29"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5791815"],"repository":["biostudies-literature"],"pubmed_title":["linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer."],"pmcid":["PMC5791815"],"pubmed_authors":["Abdul-Rahman U","Gyorffy B","Adams BD"],"additional_accession":[]},"is_claimable":false,"name":"linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer.","description":"LncRNAs are novel noncoding RNAs involved in the epigenetic regulation of gene expression by recruiting ribonucleoprotein complexes to specific genomic loci to initiate histone methylation and/or other chromatin modifications. LncRNAs themselves function as tumor suppressors or oncogenes, depending on the gene regulatory networks they govern. We identified lnc00673 (ERRLR01) as a marker of overall survival (OS) in breast cancer patients. Specifically, ERRLR01 levels were elevated in triple-negative breast cancer (TNBC) as compared with Luminal-A, Luminal-B, and HER2 breast cancer subtypes. ERRLR01 levels were also inversely correlated with breast cancer survival across all breast cancer patients. Upon stratification, OS in ERα<sup>-</sup> tumors correlated with negative overall survival, while in ERα<sup>+</sup> tumors, ERRLR01 correlated with positive outcomes. This suggests ERRLR01 is modulated by hormone signaling in breast cancer. Gene-network analysis revealed ERRLR01 correlated with distinct pathways including \"epithelial development\" and \"cellular differentiation.\" These data suggest ERRLR01 operates as an oncogene in TNBC, as well as a biomarker in breast cancer patients.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2025-04-19T02:04:01.771Z","creation":"2019-03-26T23:58:50Z"},"accession":"S-EPMC5791815","cross_references":{"pubmed":["28795861"],"doi":["10.1080/21541264.2017.1329684"]}}